Compare 8x8 Inc (EGHT) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

EGHT trades at $2.05, up 0.49% today, with a mixed technical picture showing bullish oscillators but bearish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected profitability in 2026. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus remains divided with a $19.77 price target representing significant upside potential from current levels.

The stock presents a high-risk, high-reward opportunity with substantial upside if the company achieves projected profitability, though current negative earnings and high debt levels pose execution risks. Institutional interest is growing with recent position increases, but the stock requires careful monitoring of Q3 2026 earnings results and debt management progress.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.